Sarcoma  >>  gemcitabine 
Welcome,         Profile    Billing    Logout  

53 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
gemcitabine / Generic mfg.
ChiCTR1800019995: A Clinical Study for the Efficacy and Safety of Apatinib Combined with Gemcitabine plus Paclitaxel in Patients with Advanced Hepatosarcomatoid Carcinoma

Not yet recruiting
4
40
 
Apatinib 250mg, po, qd+Gemcitabine, iv, d1, d8+Paclitaxel, iv, d1
First Affiliated Hospital of Zhengzhou University; First Affiliated Hospital of Zhengzhou University, Self-pay
Advanced Hepatosarcomatoid Carcinoma
 
 
2009-014907-29: A prospective randomised controlled phase III trial of gemcitabine and docetaxel compared with doxorubicin as first line treatment in previously untreated advanced unresectable or metastatic soft tissue sarcomas

Ongoing
3
250
Europe
Doxorubicin, Docetaxel, Gemcitabine,
University College London
Locally advanced unresectable or metastatic soft tissue sarcoma.
 
 
2010-023484-17: Sarcomas de partes blandas localizados de alto riesgo de extremidades y pared de tronco en adultos: un enfoque integrador que incluye tratamiento con medicamentos antitumorales estándar comparado con tratamientos específicos para las diferentes variedades histológicas como primer tratamiento.

Ongoing
3
250
Europe
epirrubicina, ifosfamida, Gemcitabina, Docetaxel, Etoposido, FARMIBLASTINA, Dacarbazina, epirubicin, ifosfamide, gemcitabine, docetaksel, etoposide, dacarbazine, epirubicin, ifosfamide, gemcitabine, docetaksel, etoposide, dacarbazine
ITALIAN SARCOMA GROUP, Grupo Español de Investigación en Sarcomas, Italian Sarcoma Group, , Grupo Español de Investigación en Sarcomas, NHS (diagnostic and therapeutic procedures), Eurosarc, funded by project/grant FP7
High risk localized soft tissue sarcomas typical of the adult
 
 
NCT06370871: Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma

Not yet recruiting
3
263
NA
Brigimadlin, BI 907828, Ezabenlimab, BI 754091, Gemcitabine, Docetaxel
Boehringer Ingelheim
Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS), Myxofibrosarcoma (MFS)
07/26
10/28
ISG-STS-1001, NCT01710176: Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy

Active, not recruiting
3
550
Europe
epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3), gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8), trabectedin 1.3 mg/m2, high-dose ifosfamide 14 g/m2, given in in 14 days, etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3), gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
Italian Sarcoma Group, French Sarcoma Group, Grupo Espanol de Investigacion en Sarcomas
Localized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults
06/24
06/24
ARGSARC, NCT05712694: Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma

Recruiting
3
300
Canada, US, RoW
ADI PEG20, Pegargiminase, Placebo
Polaris Group
Soft Tissue Sarcoma
12/27
12/27
jRCTs031180003: JCOG1306:Randomized phase II/III study of adjuvant chemotherapy with Adriamycin+Ifosfamide vs Gemcitabine+Docetaxel for high-grade soft tissue sarcoma ( AI vs GD for STS RPII/III )

Completed
2/3
140
Japan
ifosfamide - Generic mfg., gemcitabine - Generic mfg., docetaxel - Generic mfg.
Okayama University Hospital
Soft tissue sarcoma
 
 
2014-000259-99: A comparison of four widely used chemotherapy regimens for the treatment of Ewing sarcoma, a type of bone cancer, to see which is most effective and/or has the fewest side effects.

Ongoing
2/3
400
Europe
Cyclophosphamide, Topotecan, Irinotecan, Temozolomide, Gemcitabine, Docetaxel, Ifosfamide, Cyclophosphamide, Topotecan, Irinotecan, Temozolomide, Gemcitabine, Docetaxel, Ifosfamide, Infusion, Capsule, hard, , Cyclophosphamide, HYCAMTIN, CAMPTO, Temodal, GEMZAR, TAXOTERE, Ifosfamide
University of Birmingham, UNIVERSITY OF BIRMINGHAM, European Commission, German Cancer Aid
Recurrent and refractory Ewing sarcoma, Ewing sarcoma, a type of bone cancer, that has either grown during initial treatment or has grown after the end of treatment., Diseases [C] - Cancer [C04]
 
 
2019-002662-12: A multicentric randomized phase II/III evaluating TSR-042 (anti-PD-1 mAb) in combination with Niraparib (parpi) versus Niraparib alone compared to chemotherapy in the treatment of metastatic or recurrent endometrial or ovarian carcinosarcoma after at least one line of chemotherapy Etude de phase II/III, randomisée, multicentrique évaluant le TSR-042 (anti-PD-1 mAb) associé au Niraparib versus le Niraparib seul comparé à la chimiothérapie chez des patientes atteintes d’un carcinosarcome métastasique ou en récidive de l’ovaire ou de l’endomètre après une chimiothérapie de première intention

Not yet recruiting
2/3
196
Europe
NIRAPARIB, DOSTARLIMAB, TSR-042, Capsule, Powder for solution for infusion, Concentrate for solution for infusion, Solution for infusion, Solution for solution for infusion, NIRAPARIB, GEMCITABINE, PACLITAXEL, DOXORUBICINE LIPOSOMALE PEGYLEE, TOPOTECAN, DOXORUBICINE IV
ARCAGY-GINECO, TESARO
metastatic or recurrent endometrial or ovarian carcinosarcoma, metastatic or recurrent endometrial or ovarian carcinosarcoma, Diseases [C] - Cancer [C04]
 
 
2012-001106-26: TRIAL PHASE II MULTICENTER FOR CANCER PATIENTS DIAGNOSED WITH OSTEOSARCOMA WITH METASTASIS WHO HAVE ALREADY BEEN TREATED PREVIOUSLY ESTUDIO FASE II MULTICENTRICO PARA PACIENTES DIAGNOSTICADOS DE CANCER TIPO OSTEOSARCOMA CON METASTASIS QUE YA HAN SIDO TRATADOS PREVIAMENTE

Ongoing
2
33
Europe
Concentrate and solvent for solution for infusion, Oral solution, GEMCITABINE, RAPAMUNE
JAVIER MARTÍN BROTO, Dirección General de Farmacia y Productos Sanitarios del Ministerio de Sanidad, Política Social e Igualdad
Patients diagnosed with metastatic osteosarcoma cancer types that have been treated with chemotherapy and have active disease that permits to receive this treatment combination. Pacientes diagnosticados de osteosarcoma metastásico que han sido tratados con quimioterapia y tienen enfermedad que permite recibir esta combinación de tratamiento., Patients with metastatic osteosarcoma cancer that have been treated with standard chemotherapy and have active disease requiring treatment. Pacientes diagnosticados de cáncer tipo osteosarcoma metastásico que han sido tratados y tienen enfermedad activa, necesitando recibir tratamiento para su enfermedad., Diseases [C] - Cancer [C04]
 
 
2005-001709-24: Estudio en fase II, abierto, multicéntrico, prospectivo y aleatorizado, con DTIC o la combinación de Gemcitabina y DTIC en sarcomas de partes blandas avanzados del adulto

Ongoing
2
110
Europe
gemcitabina, M01/142, Gemzar, Gemzar
Grupo Español de Investigación en Sarcomas (GEIS)
Sarcomas de partes blandas
 
 
2020-000741-13: Trial assessing the activity of TrabectedIn vs gemCitabine in patients with advanced LEiomyosarcoma Studio sull’attività della Trabectedina vs Gemcitabina in pazienti con leiomiosarcoma avanzato pretrattati c

Not yet recruiting
2
100
Europe
Trabectedina, Gemcitabina, [trabectedina], [Gemcitabina], Powder for infusion, Concentrate for solution for infusion, Yondelis, GEMCITABINA ACCORD - 100 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 2 ML
ITALIAN SARCOMA GROUP, Pharmamar
metastatic or locally advanced Leiomyosarcoma pretreated with conventional chemotherapy leiomiosarcoma metastatico o localmente avanzato pretrattati con chemioterapia convenzionale, advanced Leiomyosarcoma leiomiosarcoma avanzato, Diseases [C] - Cancer [C04]
 
 
ChiCTR1800016587: Comparison of efficacy between GD and IE as second-line chemotherapy regimens in advanced soft tissue sarcoma: a phase II randomized controlled trial

Not yet recruiting
2
266
 
Gemcitabine with Docetaxel ;Ifosfamide with Etoposide
West China Hospital, Sichuan University; West China Hospital, Sichuan University, Self financing
soft tissue sarcoma
 
 
2018-003835-31: Targeting ATR in soft-tissue sarcomas: a randomized phase II study. TARSARC study Ciblage d’ATR dans les sarcomes des tissus mous : une étude randomisée de phase II. Etude TARSARC

Not yet recruiting
2
72
Europe
Berzosertib, GEMCITABINE, M6620, Solution for infusion, GEMCITABINE
Institut Bergonié, Merck Healthcare KGaA
Locally advanced/unresectable and/or metastatic soft-tissue leiomyosarcomas Léiomyosarcomes localement avancés et/ou métastatiques, Locally advanced/unresectable and/or metastatic soft-tissue leiomyosarcomas Léiomyosarcomes localement avancés et/ou métastatiques, Diseases [C] - Cancer [C04]
 
 
EAGLES, NCT03536780: Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment

Recruiting
2
38
RoW
Avelumab and Gemcitabine
Gachon University Gil Medical Center, Merck KGaA, Darmstadt, Germany, Chong Kun Dang Pharmaceutical Corp.
Leiomyosarcoma Metastatic
12/21
12/22
NCI-2014-00620, NCT02101775: Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Active, not recruiting
2
124
Canada, US, RoW
Adavosertib, AZD-1775, AZD1775, MK-1775, MK1775, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Pharmacological Study, Placebo Administration, Questionnaire Administration
National Cancer Institute (NCI)
Ovarian Brenner Tumor, Ovarian Carcinosarcoma, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
02/22
02/25
NCT03912818: Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Terminated
2
7
US
Carboplatin, Carboplat, Carboplatino, Carbosol, Paraplatin, Paraplatine, Cisplatin, Abiplatin, Briplatin, Cis-platinum, Cismaplat, Citoplatino, Plastistil, Platinol, Cystectomy, Doxorubicin, Adriablastin, Hydroxyl Daunorubicin, Rubex, Durvalumab, Imfinzi, MEDI-4736, Gemcitabine, Difluorodeoxycytidine, Gemzar, Methotrexate, Abitrexate, Amethopterin, Brimexate, Methotrexate Methylaminopterin, Metotrexato, Vinblastine, Vincaleucoblastine, Vinblastine Sulfate, vincaleukoblastine, sulfate
Stanford University, AstraZeneca
Bladder Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma With Giant Cells, Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation, Infiltrating Bladder Urothelial Carcinoma With Trophoblastic Differentiation, Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant, Infiltrating Bladder Urothelial Carcinoma, Nested Variant, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant
08/22
08/22
NCT02203760 / 2012-003810-15: Pazopanib vs. Pazopanib Plus Gemcitabine

Active, not recruiting
2
58
Europe
Pazopanib plus Gemcitabine, Votrient and Gemzar, Pazopanib, Votrient
North Eastern German Society of Gynaecological Oncology, Novartis Pharmaceuticals, medac GmbH
Leiomyosarcoma or Carcinosarcoma
12/24
12/24
NCT04183062: BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases

Active, not recruiting
2
10
US
Chemotherapy (gemcitabine & docetaxel) plus BIO-11006
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Osteosarcoma Metastatic, Ewing's Sarcoma Metastatic
11/23
11/24
PROACH, NCT03742193: Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy

Active, not recruiting
2
43
RoW
Apatinib, VEGFR Inhibitor, GD regimen, Chemotherapy
Ruijin Hospital
Osteosarcoma, Pulmonary Metastases, Apatinib
11/23
12/23
NCT02945800: Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma

Active, not recruiting
2
59
US
nab-Paclitaxel, Abraxane, Gemcitabine, Gemzar
H. Lee Moffitt Cancer Center and Research Institute, National Pediatric Cancer Foundation
Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Soft Tissue Sarcoma
01/24
12/24
NCT04727242: CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma

Recruiting
2
25
US
Gemcitabine, Gemzar, Infugem, difluorodeoxycytidine hydrochloride, Dacarbazine, Dimethyl (triazeno) imidazolecarboxamide, Dacarbazine - DTIC, Biocarbazine, Cytoreductive Surgery, Functional Assessment of Cancer Therapy (FACT) G questionnaire, Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Scan, Gadolinium
Kristen Ganjoo
LMS - Leiomyosarcoma, Uterine Leiomyosarcoma
01/25
01/25
NCT05275426: A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor

Recruiting
2
24
US
LY2880070, Gemcitabine
Memorial Sloan Kettering Cancer Center
Ewing Sarcoma, Ewing-Like Sarcoma
03/25
03/25
NCT05481645: Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Recruiting
2
79
RoW
TQB2450 injection, Anlotinib Hydrochloride Capsule, Carboplatin Injection, Paclitaxel Injection, Doxorubicin Hydrochloride Injection, Gemcitabine Hydrochloride Injection, Docetaxel injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Endometrial Cancer, Sarcoma of Uterus
06/24
12/24
ISG-ARTICLE, NCT04383119: Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma

Recruiting
2
100
Europe
Trabectedin, Trabectedin arm, Gemcitabine, Gemcitabine arm, No Intervention: Observational Cohort
Italian Sarcoma Group, PharmaMar
Leiomyosarcoma of Ovary, Soft Tissue Sarcoma
06/24
09/24
TAGGED, NCT04535271: Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma

Recruiting
2
80
US
Trabectedin, Gemcitabine, Dacarbazine
Sarcoma Oncology Research Center, LLC
Leiomyosarcoma
09/24
12/24
TARSARC, NCT04807816: Targeting ATR in Soft-tissue Sarcomas

Recruiting
2
72
Europe
Association of berzosertib with gemcitabine, Experimental, Gemcitabine, Control
Institut Bergonié, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Leiomyosarcoma, Adult
10/24
04/26
Actuate 1801, NCT03678883: 9-ING-41 in Patients With Advanced Cancers

Active, not recruiting
2
350
Europe, Canada, US
9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar
Actuate Therapeutics Inc.
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
11/24
11/25
ChiCTR2100053490: A phase 2 study of Surufatinib in patients after first line standard chemotherapy or Anlotinib treatment failure of soft tissue sarcoma

Recruiting
2
64
 
Surufatinib+Gemcitabine ;Surufatinib
Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University, Part of self-raised, part of Hutchison Whampoa Pharmaceuticals (Shanghai) Co., Ltd.
Soft Tissue Sarcoma
 
 
GALLANT, NCT04535713: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma

Recruiting
2
260
US
Gemcitabine, Gemzar, Doxorubicin, Adriamycin, Docetaxel, Taxotere, Nivolumab, Opdivo
Sarcoma Oncology Research Center, LLC
Sarcoma
09/25
12/25
SeliSarc, NCT06114004: Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma

Recruiting
2
88
Europe
Selinexor 20 MG, KPT-330, Gemcitabine
Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas
Sarcoma,Soft Tissue
05/26
05/26
PROMIS, NCT06114225: Pulmonary Resectable Osteosarcoma Treated by Metastasectomy and Pre-operative Immunotherapy and Stereotactic Body Radiotherapy (): a Prospective Clinical Trial

Recruiting
2
43
RoW
metastasectomy and pre-operative immunotherapy (gemcitabine and penpulimab ) and stereotactic body radiotherapy
Ruijin Hospital
Osteosarcoma
09/26
12/26
NCT02364713: MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

Active, not recruiting
2
66
US
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter, MV-NIS, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pegylated Liposomal Doxorubicin Hydrochloride, ATI-0918, Caelyx, Dox-SL, Doxil, Doxilen, Doxorubicin HCl Liposomal, Doxorubicin HCl Liposome, Doxorubicin Hydrochloride Liposome, Duomeisu, Evacet, LipoDox, Lipodox 50, Liposomal Adriamycin, Liposomal Doxorubicin Hydrochloride, Liposomal-Encapsulated Doxorubicin, Pegylated Doxorubicin HCl Liposome, S-Liposomal Doxorubicin, Stealth Liposomal Doxorubicin, TLC D-99, Quality-of-Life Assessment, Quality of Life Assessment, Topotecan Hydrochloride, Hycamptamine, Hycamtin, SKF S-104864-A, Topotecan HCl, topotecan hydrochloride (oral)
Mayo Clinic, National Cancer Institute (NCI)
Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Carcinosarcoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
03/27
02/28
GEMMK, NCT03123276: Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma

Active, not recruiting
1/2
24
Europe
Pembrolizumab, Keytruda, Gemcitabine
Royal Marsden NHS Foundation Trust, Merck Sharp & Dohme LLC
Sarcoma
02/23
02/23
NCT05093322 / 2021-003602-41: A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

Completed
1/2
13
US
Surufatinib in combination with Gemcitabine, HMPL-012, sulfatinib in combination with Gemcitabine
Hutchmed, HUTCHMED Limited
Solid Tumor, Lymphoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
04/23
04/23
ZN-c3-003, NCT04833582 / 2021-000021-27: A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma

Active, not recruiting
1/2
84
Europe, US
ZN-c3, Gemcitabine, Gemzar
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Osteosarcoma
08/23
12/23
NCT03997968: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Active, not recruiting
1/2
170
US
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Cyteir Therapeutics, Inc.
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
07/24
12/24
NCT03598595: Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

Active, not recruiting
1/2
31
US
Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Hydroxychloroquine
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Recurrent Osteosarcoma, Refractory Osteosarcoma
09/24
09/24
NCT04577014: Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

Active, not recruiting
1/2
67
US
Retifanlimab, INCMGA00012, Gemcitabine, Docetaxel
Memorial Sloan Kettering Cancer Center, Incyte Corporation
Soft Tissue Sarcoma, Sarcoma,Soft Tissue, Sarcoma, Soft Tissue Sarcoma Adult
09/25
09/25
NCT02632448: A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

Recruiting
1/2
229
Europe, Canada, US, RoW
LY2880070, Gemcitabine, Gemzar
Esperas Pharma Inc.
Solid Tumors, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Colon Cancer, Rectal Cancer, Neoplasms, Endometrial Cancer, Soft Tissue Sarcoma, Triple Negative Breast Cancer, Pancreas Cancer, Pancreatic Cancer
09/25
09/25
TINKS, NCT05634369: A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue

Recruiting
1/2
50
US
GEM/DOX + TGFBi expanded NK cells, Docetaxel, Dexamethasone, Pegfilgrastim, Gemcitabine
Nationwide Children's Hospital, National Pediatric Cancer Foundation
Pediatric Sarcoma, Refractory, Pediatric Sarcoma, Relapsed
12/26
12/27
NCT02959164: Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma

Completed
1b
36
US
Decitabine, Dacogen, Gemcitabine, Gemzar
Mohammed Milhem, Holden Comprehensive Cancer Center, University of Iowa
Pancreatic Ductal Adenocarcinoma, Sarcoma
09/19
10/20
NCT01803152: Dendritic Cell Vaccine for Children and Adults With Sarcoma

Active, not recruiting
1
19
US
Dendritic Cells Vaccine, DC Vaccine, Lysate of Tumor, Lysate, Tumor Lysate, Gemcitabine, Gemzar, Imiquimod, Aldara, Leukapheresis, Pheresis
Macarena De La Fuente, MD
Sarcoma, Soft Tissue Sarcoma, Bone Sarcoma
09/19
07/24
SJDAWN, NCT03434262: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Completed
1
68
US
Gemcitabine, Gemzar®, ribociclib, LEE011, LEE-011, KISQALI®, sonidegib, LDE225, LDE-225, ODOMZO®, trametinib, TMT212, TMT-212, MEKINIST(TM), filgrastim, G-CSF
St. Jude Children's Research Hospital, Novartis Pharmaceuticals
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Pleomorphic Xanthoastrocytoma, Anaplastic, Atypical Teratoid/Rhabdoid Tumor, Brain Cancer, Brain Tumor, Central Nervous System Neoplasms, Choroid Plexus Carcinoma, CNS Embryonal Tumor With Rhabdoid Features, Ganglioneuroblastoma of Central Nervous System, CNS Tumor, Embryonal Tumor of CNS, Ependymoma, Glioblastoma, Glioma, Glioma, Malignant, Medulloblastoma, Medulloblastoma; Unspecified Site, Medulloepithelioma, Neuroepithelial Tumor, Neoplasms, Neoplasms, Neuroepithelial, Papillary Tumor of the Pineal Region (High-grade Only), Pediatric Brain Tumor, Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only), Pineoblastoma, Primitive Neuroectodermal Tumor, Recurrent Medulloblastoma, Refractory Brain Tumor, Neuroblastoma. CNS, Glioblastoma, IDH-mutant, Glioblastoma, IDH-wildtype, Medulloblastoma, Group 3, Medulloblastoma, Group 4, Glioma, High Grade, Neuroepithelial Tumor, High Grade, Medulloblastoma, SHH-activated and TP53 Mutant, Medulloblastoma, SHH-activated and TP53 Wildtype, Medulloblastoma, Chromosome 9q Loss, Medulloblastoma, Non-WNT Non-SHH, NOS, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, PTCH1 Mutation, Medulloblastoma, WNT-activated, Ependymoma, Recurrent, Glioma, Recurrent High Grade, Glioma, Recurrent Malignant, Embryonal Tumor, NOS, Glioma, Diffuse Midline, H3K27M-mutant, Embryonal Tumor With Multilayered Rosettes (ETMR), Ependymoma, NOS, WHO Grade III, Ependymoma, NOS, WHO Grade II, Medulloblastoma, G3/G4, Ependymoma, RELA Fusion Positive
09/22
05/24
NCT04521686: Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Active, not recruiting
1
200
Europe, Japan, US, RoW
LY3410738, Gemcitabine, LY188011, Cisplatin, Durvalumab
Eli Lilly and Company, Loxo Oncology, Inc.
Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
07/23
05/25
NCT04037527: Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities

Suspended
1
27
US
Gemcitabine, Docetaxel, Taxotere, Radiation, Surgical Resection, Blood draws
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Soft Tissue Sarcoma
09/24
09/24
SELISARC, NCT04595994: Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma and Osteosarcoma

Recruiting
1
14
Europe
Selinexor, Gemcitabine
Grupo Espanol de Investigacion en Sarcomas
Sarcoma,Soft Tissue
11/25
05/26
NCT06308419: A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions

Not yet recruiting
1
12
US
Gemcitabine, Gemcitabine Hydrochloride, Gemzar®, Nab-Sirolimus
M.D. Anderson Cancer Center, Aadi Bioscience
Leiomyosarcoma, Soft-tissue Sarcomas
02/29
02/31
NCT04634227: Gemcitabine Plus Ascorbate for Sarcoma in Adults (Pilot)

Recruiting
1
40
US
Ascorbate
Mohammed Milhem, MBBS, University of Iowa
Sarcoma, Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Bone Tumor, Bone Sarcoma
08/24
08/24
NCT04877587: Gemcitabine With Ascorbate Including Adolescents

Withdrawn
1
20
US
Ascorbate, Vitamin C, Gemcitabine, Gemzar®
David Dickens
Soft Tissue Sarcoma, Bone Sarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Bone Sarcoma, Metastatic Soft-tissue Sarcoma, Unresectable Bone Sarcoma
05/25
05/25
IGM-8444-001, NCT04553692: Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers

Recruiting
1
430
Europe, US, RoW
Aplitabart (IGM-8444), FOLFIRI, Fluorouracil or 5-FU, Leucovorin, Irinotecan, Bevacizumab (and approved biosimilars), Avastin, Birinapant, Venetoclax, Venclexta, Gemcitabine, Gemzar, Docetaxel, Taxotere, Docefrez, Azacitidine, VIDAZA
IGM Biosciences, Inc.
Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma, Chondrosarcoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia
06/26
08/27
ChiCTR2000030250: Phase II clinical trial of albumin-bound paclitaxel plus gemcitabine in the treatment of metastatic/locally unresectable soft tissue sarcoma: a single-center, open, single-arm study

Recruiting
N/A
35
 
albumin-bound paclitaxel plus gemcitabine
Department of Orthopedics, the Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital; The Affiliated Cancer Hospital of Zhengzhou University, self-raised
Soft tissue sarcoma
 
 
ChiCTR2000036618: Precision therapy strategy for osteosarcoma based on molecular typing: a prospective, single-center, one-brachial umbrella phase II exploratory clinical study

Not yet recruiting
N/A
18
 
Everolimus 5mg qd + Anlotinib 8mg-12mg day 1-21，28-day cycle ;Camrelizumab 3mg/kg + Ipilimumab 1 mg/kg, 21-days cycle ;Palbociclib 125mg day 1-21 + gemcitabine 600mg/m2 day 1,8,15,22, 28-days cycle ;Olaparib 300mg bid day 1-14 + gemcitabine 600mg/m2 day 1,8,15,22, 28-days cycle ;Metformin 2000mg qd + gemcitabine 675mg/m2 day 1,8, docetaxol 900mg/m2 day 8， 21-days cycle
Shanghai General Hospital; Shanghai General Hospital, Project special fund
osteosarcoma
 
 

Download Options